Rationale for Considering Oral Idasanutlin as a Therapeutic Option for COVID-19 Patients
covid-19, antiviral activity, SARS-CoV-2, p53, MDM2, idasanutlin
Giorgio Zauli, Veronica Tisato, Paola Secchiero